CureVac NV (Germany) Investor Sentiment

5CV Stock  EUR 2.78  0.03  1.07%   
Roughly 61% of CureVac NV's investor base is looking to short. The analysis of current outlook of investing in CureVac NV suggests that many traders are alarmed regarding CureVac NV's prospects. The current market sentiment, together with CureVac NV's historical and current headlines, can help investors time the market. In addition, many technical investors use CureVac NV stock news signals to limit their universe of possible portfolio assets.
CureVac NV stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of CureVac daily returns and investor perception about the current price of CureVac NV as well as its diversification or hedging effects on your existing portfolios.
  
over a year ago at news.google.com         
Notable Two Hundred Day Moving Average Cross - CVAC - Nasdaq
Google News at Macroaxis
over a year ago at news.google.com         
CureVac N Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income - F...
Google News at Macroaxis
over a year ago at news.google.com         
CureVac Files Expanded Patent Lawsuit Against PfizerBioNTech ... - U.S News World Report Money
Google News at Macroaxis
over a year ago at news.google.com         
Some Analysts Just Cut Their CureVac N.V. Estimates - Simply Wall St
Google News at Macroaxis
over a year ago at news.google.com         
Certain Restricted Stock Units of CureVac N.V. are subject to a Lock ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Certain Restricted Stock Units of CureVac N.V. are subject to a Lock-Up Agreement Ending on 9-APR-20...
Google News at Macroaxis
over a year ago at news.google.com         
Private equity firms are CureVac N.V.s biggest owners and were rewarded after market cap rose by US1...
Google News at Macroaxis
over a year ago at news.google.com         
mRNA Therapeutics Market to Reach USD 45.40 Billion by 2030 as a Result of Advances in Technology, P...
Google News at Macroaxis
over a year ago at news.google.com         
CureVac Announces Voting Results of Extraordinary General Meeting - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
CureVac NASDAQCVAC shareholders incur further losses as stock declines 8.3 percent this week, taking...
Google News at Macroaxis
over a year ago at news.google.com         
PfizerBioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents - Modern...
Google News at Macroaxis
over a year ago at news.google.com         
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher ... - Science
Google News at Macroaxis
over a year ago at news.google.com         
German CureVac to offer ordinary shares - European Biotechnology News
Google News at Macroaxis
over a year ago at news.google.com         
Why CureVac Shares Are Gaining Today - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
Fridays Top Analyst Upgrades and Downgrades Alcoa, Charles Schwab, IBM, Newmont, Philip Morris, Robl...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about CureVac NV that are available to investors today. That information is available publicly through CureVac media outlets and privately through word of mouth or via CureVac internal channels. However, regardless of the origin, that massive amount of CureVac data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CureVac NV news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CureVac NV relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CureVac NV's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CureVac NV alpha.

CureVac NV Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for CureVac Stock analysis

When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios